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ABSTRACT 
A new congenital dysfibrinogenemia. designated fibrinogen Petoskey, 
which was traced through four generationsof a Michigan family, was 
found to exhibit an abnormally slow rate of release of fibrino- 
peptide A upon treatment with thrombin and batroxobin. Batroxobin 
only partially hydrolyzed and polymerized the fibrinogen from 
affected individuals,suggesting that these patients had both normal 
and abnormal fibrinogen in their circulation and that batroxobin 
was not capable of releasing fibrinopeptide A from the abnormal 
fibrinogen. Polymerization of fibrin monomers from fibrinogen 
Petoskey and plasmin mediated digestion of fibrinogen Petoskey were 
normal. The Factor XIIIa-catalyzed cross-linking of fibrinogen 
Petoskey was slightly delayed at low (but not at high) concen- 
trations of thrombin. This delayed cross-linking appeared to be a 
secondary effect of the lower rate of release of fibrinopeptide A. 
The first report of a functional abnormality in fibrinogen appeared in 
1958 (1). Since then over 50 congenital dysfibrinogenemias have been report- 
ed. (See 2.3.4 for reviews discussing most of the known dysfibrinogenemias). 
Although in most affected individuals the concentration of fibrinogen and 
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other clotting factors is normal, fibrinogen from affected individuals usual- 
ly exhibits a prolonged thrombin clotting time or a prolonged prothrombin 
time (or both). The affected step in the clotting process has been determin- 
ed in many of these dysfibrinogenemias. In some cases, the rate of proteoly- 
sis and release of fibrinopeptide A or B is decreased due to an alteration in 
interactions between the thrombin and fibrinogen. In other cases, altered 
rates of spontaneous polymerization of fibrin monomers or altered rates of 
Factor XIIIa-mediated cross-linking of fibrin are observed. In addition to 
showing one or more of these functional defects, fibrinogen from individuals 
with certain dysfibrinogenemias exhibits altered degradation rates and 
products upon digestion with plasmin. 
Only two dysf ibrinogenemias (fibrinogens Paris I and Detroit) have been 
characterized on a molecular level. In fibrinogen Paris I (5). a fraction of 
the Y-chains is elongated, and in fibrinogen Detroit (6), Arg-19 of the 
Au-chains is replaced by Ser. Detailed functional and structural studies of 
inherited abnormal fibrinogens provide a powerful method for characterizing 
interactions of fibrinogen which are important in the formation of a 
functionally competent blood clot. In the case of fibrinogen Detroit such a 
study (6) has revealed that interactions involving aminoacyl residues at the 
amino termini of the a-chains are necessary for polymerization of fibrin and 
thrombin mediated cleavage of fibrinopeptide B from the B3-chains. 
The present report describes a new congenital abnormality in a Michigan 
family (7). characterized by fibrinogen which shows abnormally slow release 
of fibrinopeptide A with thrombin and resistance to proteolysis by batroxobin 
(reptilase). It is anticipated that further study of this fibrinogen will 
increase our understanding of the structural determinants of the interaction 
between thrombin and fibrinogen. 
Normal human plasma was obtained from the American Red Cross. It had 
been prepared from 450 ml of whole blood collected into 63 ml of citrate 
phosphate dextrose ant icoagulant. Plasma from affected individuals was 
prepared from whole blood collected in a similar manner. All plasma was 
stored frozen. 
. . Flbrlnoeen w Durified from plasma by glycine precipitations to obtain 
fraction I-2 as described previously (a), and was further purified to frac- 
tion I-4 by the method of Blomback and BlombPck (9). Contaminating plasmino- 
gen was removed by passing fraction I-4 through a lysine-Sepharose column 
(10). The resulting fibrinogen preparations were at least 95% clottable. 
m clottabilitv nf m was determined by a modification of the 
method of Mosesson and Sherry (8) and Laki (11)) in which the absorbance at 
280 nm was measured before and after clotting. In this procedure, 0.94 ml of 
fibrinogen in 0.3 M NaCl was mixed with 50 ul of a 0.64 M potassium phosphate 
buffer which brought the pH of the resulting solution to 6.4. The solution 
was clotted by the addition of 1 IJ of human thrombin (labeled greater than 
3000 U/mg as obtained from Sigma Chemical Company. St. Louis, Missouri) in 
10 ul. After 3 hours at room temperature the clot was removed and the 
absorbance (280 nm) of the clot supernatant was determined and compared to 
the absorbance of a diluted sample of the original fibrinogen solution. The 
clottability of fibrinogen from affected individuals was determined in a 
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similar manner, except that 5 U of human thrombin in 10 ~1 was used to clot 
the fibrinogen. 
coagulation w. including thrombin clotting time (12). 
prothrombin time (13) and partial thromboplastin time (14). were performed by 
standard procedures, and the results obtained with patients' plasma were 
compared to those obtained with pooled normal plasma. Factor V and Factor 
VIII levels were measured by modifications of the methods used to determine 
prothrombin time (13) and partial thromboplastin time (14), respectively. 
Factor XIII levels were measured as described by Duckert &a. (15). 
Fibrinogen concentrations were determined by the thrombin clotting time assay 
of Clauss (16) or by assay of the fibrin tyrosine content (17). 
. . 
IhzadLkandbatroxoblnmedlated *_ * were studied by the 
following modification of the method of Gralnick & a. (18). A fibrinogen 
solution (0.15 ml) in 0.3 M NaCl was equilibrated at 25'C in a cuvette with 
1.35 ml of 0.06 M sodium phosphate buffer, pH 6.8. Either 10 ~1 thrombin or 
50 vl batroxobin (reconstituted Reptilase-R obtained from Abbott Laborator- 
ies, North Chicago, Illinois) was added and the absorbance at 350 nm was con- 
tinuously monitored in a thermostated cell compartment of a GCA/McPherson 
spectrophotometer. 
. . m pf EEB were done with a kit from IMCO Corp., Ltd. AB 
Stockholm. Sweden. Samples were prepared using hirudin to inhibit the 
thrombin (19). 
m m amount pf v released upon treating fibrinogen 
with thrombin was measured as described previously (18) using the method of 
Lowry (20) to determine trichloroacetic acid (TCA)4 soluble peptides in the 
clot supernatant. 
Fibrin monomer were prepared and subsequently aggregated by a 
modification of the method of Gralnick aal. (18 and references cited 
therein). Fibrinogen in 0.15 M Tris-HCl buffer, 0.15 M NaCl, pH 7.4 was 
clotted with human thrombin. After approximately 90% of the fibrinogen had 
clotted. the clot was wound around a glass rod and then dissolved in 0.02 M 
acetic acid. Polymerization of the fibrin monomers was initiated by adding a 
portion of the monomer solution to a 31-fold excess of 0.06 M potasium 
phosphate buffer at pH 6.8 which either contained no NaCl (for runs at an 
ionic strength of 0.12) or 0.3 M NaCl (for runs at an ionic strength of 0.42) 
at 25'C. 
The ~c;yoss-li&i~g af fibrin was monitored as described previously (21). 
Digestion nf fibrinoeen ti Dlasmin was carried out by a method similar 
to that described by Sherman fi A. (22). Plasminogen (profibrinolysin. 
labeled 2.5 U/mg as obtained from Sigma Chemical Co., St. Louis, Missouri) at 
5 mg/ml in 0.046 M Tris-HCl, 0.115 M CaC12 pH 8.1 was activated with 100 
Plough U/ml of urokinase (obtained from Calbiochem-Behring Corp.. La Jolla, 
California) for one hour. prior to the start of digestion. 
'Abbreviations used in this paper: TCA, Trichloroacetic acid; PAGE, 
polyacrylamide gel electrophoresis; SDS, sodium dodecyl sulfate. 
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w !& electroDhoresis (PAGE) in the presence of sodium 
dodecyl sulfate (SDS) was done on slab gels as described by Laenrmli (23). 
. . drcrolsm m were obtained with a Jasco. J-40C automatic 
recording spectropolarimeter. 
I;asetlistorv. The propositus, an 80 year old Caucasian male, was first 
studied in 1977 prior to total hip replacement surgery. He was in excellent 
health, except for severe degenerative arthritis in the left hip. When 
studies of his clotting system indicated an abnormality, he was referred to 
The University of Michigan Hospital. He had no history of unusual bleeding, 
except in 1973 when he required two units of blood after a cholecystectomy. 
Coagulation studies (Table I) demonstrated that the patient's prothrom- 
bin time and thrombin clotting times were abnormally long. The partial 
thromboplastin time, and Factor V and XIII levels of the propositus were 
normal, whereas his Factor VIII level was elevated. The fibrinogen con- 
centration in the plasma of the propositus was abnormally low when measured 
using the indirect thrombin clotting time assay, and normal when measured 
from the tyrosine content of the fibrin. These studies suggested a diagnosis 
of dysfibrinogenemia, wherein the actual level of fibrinogen in the plasma 
was normal, but some of the fibrinogen was functionally deficient so as to 
give an abnormally long thrombin clotting time. 
j&~j& studies. The dysfibrinogenemia was traced through four gen- 
erations (Fig. 1). Twenty-seven of the descendants of the propositus were 
tested and eleven had prolonged thrombin clotting times. The apparent 
fibrinogen concentration based on the thrombin clotting times of affected 
individuals ranged from 59 mg/dl to 101 mg/dl. The Reptilase time determined 
for plasma from the propositus' daughter (III-4 in Fig. 1) was also found to 
be prolonged (31.5 s vs. 14.8 s for normal plasma). All affected individuals 
were asymptomatic; several had undergone surgery, including hysterectomy, 
appendectomy, cholecystectomy. and tonsillectomy with no unusual bleeding or 
requirements for blood products. There was no known consanguinity in the 
TABLE I 
Coagulation Assays on Plasma from the Propositus 
Thrombin Clotting Time 
Prothrombin Time 





Based on the Thrombin Clotting Time 
Based on the Fibrin Tyrosine Content 
13.6 s 8-9 s 
13.0 s 11 s 




96 mg/dl 200-300 mg/dl 
298 mg/dl 200-300 mg/dl 
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Pedigree of fibrinogen Petoskey 
family and the family pedigree (Fig. 1) indicated that the defect was 
inherited as an autosomal dominant trait. 
. . s pf a Defect u m. Fibrinogen purified from 
patients’ plasma was only 46% clottable after three hours with one unit of 
thrombin per ml of fibrinogen solution , whereas normal fibrinogen was greater 
than 95% clottable. When the thrombin concentration was increased to five 
U/ml, however, both the patient’s fibrinogen and normal fibrinogen were 
greater than 95% clottable. Polyacrylamide gel electrophoresis in SDS of 
fibrinogen, as well as reduced Aa-, BB-, and y-chains obtained from normal 
and affected individuals indicated that the molecular weights of the polypep- 
tide chains of fibrinogen from normal and affected individuals were similar. 
Circular dichroism spectra of both fibrinogen6 were also identical, suggest- 
ing that there was no major conformational alteration in the abnormal fibrin- 
ogen. Immunodiffusion of fibrinogen from normal individuals and affected 
family members against goat antibodies to human fibrinogen revealed complete 
lines of identity. These results suggested a close structural resemblance 
between the normal and abnormal fibrinogens. 
Mixing a patient’s plasma with normal plasma in various ratios revealed 
no inhibitory effect in thrombin clotting time when compared with normal 
plasma mixed with barbital buffered saline. A similar result was obtained 
when thrombin-mediated clotting of purified fibrinogen was studied at several 
ratios of normal fibrinogen, abnormal fibrinogen and buffer. These results 
suggest that the slower clotting of the fibrinogen from affected individuals 
was not due to an inhibitor to clotting in their plasma and that the 
fibrinogen from affected individuals had no inhibitory effect on the clot- 
ting of normal fibrinogen. 
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VpfaBhnormalFibrinoeen. The 
thrombin-catalyzed cleavage of normal and abnormal fibrinogen near the amino 
termini of the Aa- and BB-chains, to release fibrinopeptides A and B, and the 
subsequent spontaneous polymerization of the fibrin monomers (24) was 
monitored by following the increase in turbidity of the solution caused by 
the polymerization reaction. Although the increase in turbidity of the solu- 
tion reflects polymerization of fibrin monomers, subsequent to the thrombin- 
mediated proteolysis of the fibrinogen, the rate at which the turbidity of a 
solution of fibrinogen increases upon addition of thrombin may be determined 
either by the rate of proteolysis or polymerization. whichever is slower. As 
shown in Fig. 2A. a fifteen-fold increase in the concentration of thrombin 
(from 2.9 U/ml to 43.7 U/ml) had no effect on the rate of thrombin-mediated 
polymerization of normal fibrinogen as measured from the time dependent in- 
crease in turbidity. Since the increased thrombin concentration should have 
increased the rate of proteolysis, this result suggests that polymerization 
and not proteolysis was rate limiting under the conditions used with normal 
fibrinogen. The fibrinogen from an affected family member displayed markedly 
different behavior (Fig. 2B). At a low thrombin concentration (2.9 U/ml), 
thrombin-mediated polymerization of the patient's fibrinogen was much 
0 
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FIG. 2. 
Thrombin-mediated polymerization of normal fibrinogen (A), and fibrin- 
ogen from an affected individual (B). The fibrinogen (0.052 mg/ml) in 
0.054 M potassium phosphate buffer, 0.027 M NaCl. pH 6.8 was treated 
with=. 43.7 U/ml; *, 11.3 U/ml; Andy. 2.9 U/ml thrombin. 
slower than thrombin-mediated polymerization of normal fibrinogen. 
Moreover, increasing the concentration of thrombin, which presumably in- 
creased the rate of release of fibrinopeptide A and B, markedly increased the 
rate of polymerization (Fig. 2B). These observations suggested that pro- 
teolysis of abnormal fibrinogen was rate limiting under the same conditions 
where polymerization of fibrin monomers was rate limiting with normal 
fibrinogen. Differences in the rate of thrombin-mediated polymerization of 
abnormal and normal fibrinogen similar to those depicted in Fig. 2 were 
observed at all fibrinogen concentrations studied (0.05 mg/ml to 5.7 mg/ml). 
Although thrombin-mediated polymerization of the patient's fibrinogen 
was slower (at low thrombin concentrations) than that of normal fibrinogen, 
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the amounts of fibrinopeptides ultimately released were within experimental 
error (+5%) of each other as judged by Lowry (20) determinations of WA 
soluble peptide material in the clot supernatants (18). The low sensitivity 
of this procedure, however,5made it impractical to use it to compare rates of 
release of fibrinopeptides. 
. . _pfPibrinoDeDtideA. The release of fibrinopeptides 
from fibrinogen was monitored using a radioimmunoassay to obtain additional 
evidence in support of the conclusion that the abnormal fibrinogen exhibits a 
decreased rate of proteolysis. Normal fibrinogen and fibrinogen from an 
affected family member at 2.82 mg/ml (8.3 PM) were each incubated with equal 
aliquots of a dilute solution of thrombin. so as to achieve a slow rate of 
release of fibrinopeptide A which could be measured conveniently. Radio- 
immunoassay of the fibrinopeptide A released after 6 hours indicated that 
the normal fibrinogen had released 50% of fibrinopeptide A, whereas the 
abnormal fibrinogen had released only 33% of fibrinopeptide A. This result 
provided direct evidence that the rate of release of fibrinopeptide A from 
the abnormal fibrinogen is decreased. 
mand_pfFibrinoeen. The 
protease batroxobin, like thrombin, catalyzes hydrolytic cleavage of fibrin- 
opeptide A from fibrinogen (25). Batroxobin. however. does not cleave the 
Bf3- chains to release fibrinopeptide B. Thus, it was used to compare the re- 
lease of fibrinopeptide A from the fibrinogen of an affected individual with 
that of normal fibrinogen. When batroxobin was added to a solution of normal 
fibrinogen, the fibrinogen clotted completely, as measured by an increase in 
turbidity (Fig. 3). Subsequent addition of thrombin had no further effect. 
This result indicated that removal of fibrinopeptide A from normal fibrinogen 
resulted in a degree of polymerization which was sufficient to produce the 
maximal change in turbidity. The addition of batroxobin to the fibrinogen 
from an affected family member, clotted only about one quarter of the 
fibrinogen as estimated from the turbidity of the solution (Fig. 3). After 
2.5 hours when the maximum batroxobin induced polymerization was complete (as 
reflected by a constant absorbance at 350 w), the fibrin product was wound 
around a glass rod and removed. Subsequent addition of thrombin caused an 
additional rapid increase in the turbidity of the solution. This result 
suggested that a portion of the affected family’s fibrinogen was 
totally resistant to proteolysis by batroxobin. but was susceptible to 
thrombin mediated proteolysis. This view is supported by the data in 
Table II which show a decreased velocity of batroxobin mediated release of 
fibrinopeptide A from a patient’s fibrinogen. As might be expected if the 
abnormal fibrinogen molecules in the sample were totally resistant to 
batroxobin, the yield of fibrinopeptide A from the fibrinogen of a patient 
was about one half of that obtained from normal fibrinogen even when the 
patient’s fibrinogen was incubated with a large excess of batroxobin for 
prolonged times. These results. together with the slower thrombin-mediated 
release of fibrinopeptide A from a patient’s fibrinogen seen with the 
radioimmunoassay, indicated that removal of fibrinopeptide A was the 
functionally defective step in the clotting of the abnormal fibrinogen. 
'A comparative study (using HPLC) of the kinetics of the thrombin catalyzed 
release of fibrinopeptides A and B from normal fibrinogen and the fibrinogen 
of an affected family member will be the subject of another study. 
498 ABNORMAL FIBRINOGEN Vo1.23, No.6 
0 15 30 150 165 I80 195 
TIME (MIN) 
FIG. 3. 
Batroxobin- and thrombin-mediated polymerization of normal 
fibrinogen and fibrinogen from an affected individual. 
Samples were in 0.05 M potassium phosphate buffer, 0.05 M 
NaCl, pH 6.8. ??, 0.135 mg/ml normal fibrinogen; *, 0.27 
mg/ml fibrinogen from an affected individual. The concen- 
tration of the patient’s fibrinogen was twice that of the 
normal fibrinogen in order to obtain a fair comparison of 
the polymerization of the two proteins, since batroxobin 
mediated the release of fibrinopeptide A from only one 
half of the patient’s fibrinogen. At zero time, 50 nl of 
reconstituted Reptilase-R was added to each 1.35-ml sample of 
fibrinogen. After the maximum amount of polymerization had 
occurred (150 min) the clots were removed from the solution, 
causing the optical density at 350 nm to return to zero. 
Thrombin (5 U) was then added to each sample. Any increase 
in the absorbance of the sample is shown here as an addition- 
al rise in the absorbance at 350 nm. 
. . 
PolvmerrzatronpfPreformedFibrin-. Fibrin monomers were 
prepared from normal fibrinogen and the patient’s fibrinogen under conditions 
where about 90% of the fibrinogen had formed fibrin. When these monomers 
were dissociated at low pll, and then returned to a neutral pH. the monomers 
polymerized. No signif icant differences could be detected between the 
polymerization (as monitored at 350 nm) of monomers from normal and the 
patient’s fibrinogen at an ionic strength of 0.12 or 0.42. This result 
provided additional support for the view that the proteolysis step and not 
the polymerization of fibrin monomers was the altered step in the clotting of 
abnormal fibrinogen. 
&QJ&&AL m af JL&rin KFth Factor u. Fibrinogen 
preparations which had been subjected to treatment with urea to inactivate 
endogeneous Factor XIII (21) contaminants were clotted in the presence of 
CaC12, 4.4 U/ml thrombin and 1 ul/ml normal plasma so as to provide the same 
amount of Factor XIII to both samples. The progression of cross-linking was 
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TABLE II 
Batroxobin Mediated Release of Fibrinopeptide A 
From Fibrinogen of Normal Individuals and a Patienta 
Time (hr) 
Fibrinopeptide A Released b 
(nmol/ml) 
Normal Patient 
0.25 1.4 (18) 1.0 (13) 
0.50 2.7 (34) 1.7 (22) 
1 4.3 (55) 2.9 (37) 
2 6.3 (80) 3.8 (48) 
6 7.3 (93) 4.3 (55) 
6' 7.8 (99) 4.4 (56) 
aFibrinogen (1.34 mg/ml. 3.94 nmol/ml) in 0.25 M NaCl. 30 mM sodium phosphate 
pH 6.6 was incubated with 1 ul reconstituted Reptilase-R per ml fibrinogen 
solution at 37OC. At the indicated times 1 volume of 3 N perchloric acid was 
added to 10 volumes of the reaction mixture to stop the reaction. Following 
centrifugation. the amount of fibrinopeptide A in each sample was determined 
using high performance liquid chromatography as described in reference 26. 
bThe numbers in parentheses indicate the % yield of fibrinopeptide A based on 
two Aa-chains per molecule and a molecular weight of 340,000 for fibrinogen. 
‘This sample contained 100 ul reconstituted Reptilase-R per ml fibrinogen. 
evaluated by reducing the fibrin and using PAGE in SDS to determine the ex- 
tent of cross-linking of a- and g-chains. Both normal fibrinogen and the 
fibrinogen from an affected family member formed a-polymers and Y-dimers with 
the concomitant disappearance of the a-monomers and y-monomers; however, the 
rate of cross-linking differed in the two samples. After 15 min, the y-mon- 
omers could not be detected in the normal fibrinogen. but were still de- 
tectable in the sample of abnormal fibrinogen at one hour. After two 
hours, y-monomers also were no longer seen in the sample of abnormal 
fibrinogen. The disappearance of a-monomers also was delayed in the sampleof 
abnormal fibrinogen during the first hour of incubation. 
The difference in the rates of cross-linking of abnormal and normal 
fibrinogen was abolished, however , when higher concentrations of thrombin (44 
U/ml> were present. This result suggested that the delayed cross-linking is 
a secondary effect due to the slower proteolysis of the fibrinogen from an 
affected family member. The rate of formation of cross-linked fibrin from 
fibrinogen will reflect primarily the rate of the slowest step in this 
multistep process. At high thrombin concentrations where release of fibrin- 
opeptide A is probably not determining the rate of conversion of soluble 
fibrinogen to cross-linked fibrin. no difference in the rates of formation of 
normal and abnormal cross-linked fibrins should be observed. 
Degradation 9f m. Normal fibrinogen and 
fibrinogen from an affected family member were incubated with plasmin to 
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determine whether the abnormal fibrinogen exhibited altered degradation 
products. At appropriate times 2 mM a-toluenesulfonyl fluoride was added to 
samples of the incubation mixture to inhibit the plasmin. PAGE in SDS of the 
samples before and after reduction with B-mercaptoethanol indicated that the 
two fibrinogens were equally susceptible to proteolysis by plasmin. The 
degradation products formed at identical rates in the two fibrinogen samples 
and had similar molecular weights. Thus. the structural alteration in the 
abnormal fibrinogen did not lead to a detectable alteration in the normal 
pattern (27) of degradation of fibrinogen by plasmin. 
The propositus described here and several of his descendants have 
dysf ibrinogenemia, a qualitative alteration in their fibrinogen. The 
congenital disorder was traced through four generations. It appeared to be 
inherited in an autosomal dominant manner, as described for other dys- 
f ibrinogenemias (Z-4). The observation that prolonged batroxobin treatment 
of fibrinogen Petoskey mediated only partial release of fibrinopeptide A 
(56%) and the observation that batroxobin mediated only 
partial polymerization of fibrinogen indicated that there are two species of 
fibrinogen in the plasma of affected individuals. These observations provide 
biochemical proof that affected family members are heterozygotes as suggested 
by the mode of inheritance of the dysfibrinogenemia. The normal component of 
the fibrinogen Petoskey was presumed to aggregate when it was treated with 
batroxobin, because the removal of fibrinopeptide A alone is sufficient to 
support end to end polymerization of normal fibrinogen (25). 
The absorbance measurements depicted in Fig. 3 suggest that only about 
25% of the patient’s fibrinogen polymerized normally upon treatment with 
batroxobin. This result taken together with the data in Table II suggests 
that batroxobin-mediated hydrolysis of half of an affected individual’s 
fibrinogen causes polymerization of only one quarter of the fibrinogen. 
This apparent discrepancy might be due to the absorbance not being a linear 
function of the degree of polymerization. An alternative explanation also 
should be considered, however. Assuming that a single structural alteration 
in one polypeptide chain is responsible for this abnormality, equal rates of 
synthesis of the normal and abnormal polypeptide chains would result in 50% 
of either the Aa-, B6- , or y-chains containing the structural abnormality. 
For pu poses of illustration let us assume the abnormality is in the Aa- 
chain. 6 Given that each fibrinogen molecule contains two of each of the 
Au-, B6- , and y-chains. random assembly would result in a mixture in which 
25% of the molecules contained two normal Aa-chains. 25% of the molecules 
contained two abnormal Aa-chains, and 50% of the molecules contained one 
normal and one abnormal Aa-chain. If polymerization (under the experimental 
conditions used) required that both Aa-chains in a molecule be converted to 
a-chains, batroxobin treatment would be expected to polymerize only 25% of 
the fibrinogen upon release of 50% of the fibrinopeptide A. Further work is 
underway to verify this hypothesis about the assembly of fibrinogen and the 
structural requirements for polymerization. 
bTheamino acid replacement in fibrinogen Petoskey is established in another 
communication (26). 
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The dysfibrinogenemia reported in this work is one of a class of 
dysfibrinogenemias which exhibit an abnormality in the release of 
fibrinopeptide A. Of the 14 dysfibrinogenemias (18, 28-40) in this class 
only fibrinogen Bethesda I and fibrinogen New Orleans exhibit normal poly- 
merization of fibrin monomers as does the abnormal fibrinogen reported here. 
Unlike this fibrinogen, however, fibrinogen Bethesda I (18) and fibrinogen 
New Orleans (37) inhibit the thrombin clotting time of normal plasma, It is 
interesting to note that fibrinogen Metz (36). like the abnormal fibrinogen 
reported here, is resistant to proteolysis by batroxobin. Fibrin monomers 
from fibrinogen Metz, however. exhibit altered rates of polymerization. 
Therefore, the fibrinogen reported in this work appears to be unique. 
Following accepted nomenclature , we designate this new dysfibrinogenemia, 
fibrinogen Petoskey. 
Ultimately, the dysfibrinogenemias must be distinguished on the basis 
of the amino acid replacement responsible for the functional alteration. As 
exemplified by the characterization of fibrinogen Detroit (6), knowledge of 
dysfibrinogenemias should greatly enhance our understanding of the complex 
set of interactions necessary for the conversion of circulating fibrinogen to 
a covalently cross-linked fibrin clot. Fibrinogen Petoskey offers a unique 
opportunity to determine an important structural feature of fibrinogen which 
is essential for its susceptibility to batroxobin and which is important for 
its interaction with thrombin. 
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